57
Participants
Start Date
November 27, 2023
Primary Completion Date
October 30, 2025
Study Completion Date
July 21, 2026
N332-GT5 gp140 (IM, Bolus)
IM in the deltoid
N332-GT5 gp140 (IM, Fractioned)
IM in the deltoid, Fractionated escalating dose for prime
N332-GT5 gp140 (SC, Bolus)
SC in the upper arm
N332-GT5 gp140 (SC, Fractioned)
SC in the upper arm, Fractionated escalating dose for prime
SMNP (IM, Bolus)
IM in the deltoid
SMNP (IM, Fractioned)
IM in the deltoid, Fractionated escalating dose for prime
SMNP (SC, Bolus)
SC in the upper arm
SMNP (SC, Fractioned)
SC in the upper arm, Fractionated escalating dose for prime
New York Blood Center, New York
University of Rochester Medical Center, Rochester
Penn Prevention CRS [Site ID: 30310], Philadelphia
Atlanta - Hope Clinic, Decatur
Bridge HIV CRS, San Francisco
Columbia University Medical Center, New York
Brigham & Women's Hospital, Boston
Vanderbilt Institute for Infection, Immunology and Inflammation, Nashville
National Institutes of Health (NIH)
NIH
Department of Health and Human Services
FED
National Institute of Allergy and Infectious Diseases (NIAID)
NIH